S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Cassava Sciences Stock Undervalued with Its $124 Price Target?
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Cassava Sciences Stock Undervalued with Its $124 Price Target?
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Cassava Sciences Stock Undervalued with Its $124 Price Target?
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Cassava Sciences Stock Undervalued with Its $124 Price Target?
NASDAQ:APEN

Apollo Endosurgery - APEN Stock Forecast, Price & News

$9.83
-0.02 (-0.20%)
(As of 01/27/2023 08:54 PM ET)
Add
Compare
Today's Range
$9.82
▼
$9.85
50-Day Range
$5.91
▼
$10.14
52-Week Range
$3.49
▼
$10.30
Volume
802,000 shs
Average Volume
1.26 million shs
Market Capitalization
$467.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.50

Apollo Endosurgery MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
6.8% Upside
$10.50 Price Target
Short Interest
Healthy
1.03% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.17mentions of Apollo Endosurgery in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.97) to ($0.86) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.50 out of 5 stars

Medical Sector

951st out of 1,049 stocks

Surgical & Medical Instruments Industry

99th out of 105 stocks

See Top Rated MarketRank™ Stocks Here

APEN stock logo

About Apollo Endosurgery (NASDAQ:APEN) Stock

Apollo Endosurgery, Inc. is a medical technology company, which focuses on the design, development, and commercialization of medical devices to advance gastrointestinal therapeutic endoscopy. It offers Endoscopy, Surgical and Other products. The firm's endoscopy product portfolio consists of the OverStitch Endoscopic Suturing System, the OverStitch Sx Endoscopic Suturing System, and the Orbera Intragastric Balloon System. Its products are used by gastroenterologists and bariatric surgeons in a variety of settings to treat multiple gastrointestinal conditions including closure of acute perforations and chronic fistulas, inadvertent perforation of the GI tract, tissue closure after the removal of abnormal lesions in the esophagus, stomach or colon, the treatment of swallowing disorders, esophageal stent fixation, and obesity. The company was founded by Christopher J. Gostout and Dennis L. McWilliams in 2005 and is headquartered in Austin, TX.

Receive APEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Apollo Endosurgery and its competitors with MarketBeat's FREE daily newsletter.

APEN Stock News Headlines

January 25, 2023 | americanbankingnews.com
Cowen Downgrades Apollo Endosurgery (NASDAQ:APEN) to Market Perform
January 11, 2023 | benzinga.com
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Apollo Endosurgery, Inc. (APEN)
January 30, 2023 | Porter & Company (Ad)
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
December 15, 2022 | apnews.com
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – SAL, VVNT, APEN, GRAY
December 13, 2022 | finance.yahoo.com
Apollo Endosurgery Announces Two Important Milestones in the Advancement of Endoscopic Procedures for Patients Living with Obesity
December 8, 2022 | msn.com
$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,400 Today
December 5, 2022 | wsj.com
SHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Apollo Endosurgery, Inc. - APEN
November 30, 2022 | bizjournals.com
Boston Scientific shells out $615M for gastro device firm
January 30, 2023 | Porter & Company (Ad)
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
November 29, 2022 | nasdaq.com
Boston Scientific to buy Apollo Endosurgery for $417 million
November 29, 2022 | reuters.com
Boston Scientific to acquire Apollo Endosurgery in $615 mln deal
November 29, 2022 | finance.yahoo.com
Apollo Endosurgery to be Acquired by Boston Scientific
November 29, 2022 | finance.yahoo.com
Boston Scientific to acquire Apollo Endosurgery for $615 million in cash
November 21, 2022 | finance.yahoo.com
Apollo Endosurgery Completes Transition to European MDR Requirements for the OverStitch Systems, BIB and Orbera 365 intragastric balloons, and OverTube.
November 8, 2022 | finance.yahoo.com
Apollo Endosurgery, Inc. (NASDAQ:APEN) is largely controlled by institutional shareholders who own 58% of the company
November 7, 2022 | finance.yahoo.com
Apollo Endosurgery to Participate in Upcoming Investor Conferences
November 1, 2022 | finance.yahoo.com
Apollo Endosurgery, Inc. Reports Record $19.6 million Global Revenue in Third Quarter 2022
October 18, 2022 | finance.yahoo.com
Apollo Endosurgery to Report Third Quarter Results on November 1, 2022
October 12, 2022 | nasdaq.com
Investors in Apollo Endosurgery (NASDAQ:APEN) have made a favorable return of 92% over the past three years
October 10, 2022 | msn.com
Short Volatility Alert: Apollo Endosurgery, Inc.
September 26, 2022 | finance.yahoo.com
Apollo Endosurgery, Inc. (APEN)
September 17, 2022 | investing.com
Apollo Tyres Ltd (APLO)
September 6, 2022 | finance.yahoo.com
MIMEDX Announces Leadership Transition
August 31, 2022 | finance.yahoo.com
Endoscopic Sleeve Gastroplasty (ESG) Procedure Featured as a "Top 10" Paper at the IFSO 2022 World Congress in Miami
August 25, 2022 | finance.yahoo.com
Apollo Endosurgery, Inc. (NASDAQ:APEN) insider upped their holding by 160% earlier this year
August 4, 2022 | finance.yahoo.com
Apollo Endosurgery (NASDAQ:APEN) hikes 14% this week, taking three-year gains to 156%
August 4, 2022 | seekingalpha.com
Apollo Endosurgery: Collect Shares At A Discount Following Q2 Earnings
See More Headlines
Receive APEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Apollo Endosurgery and its competitors with MarketBeat's FREE daily newsletter.

APEN Company Calendar

Last Earnings
11/01/2022
Today
1/30/2023
Next Earnings (Estimated)
2/28/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:APEN
CUSIP
N/A
CIK
1251769
Web
www.apolloendo.com
Phone
(512) 279-5100
Fax
858-678-0900
Employees
202
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.50
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+6.8%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.02)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-24,680,000.00
Net Margins
-56.74%
Pretax Margin
-56.26%
Return on Equity
-78.73%
Return on Assets
-32.99%

Debt

Debt-to-Equity Ratio
1.26
Current Ratio
6.00
Quick Ratio
4.98

Sales & Book Value

Annual Sales
$62.99 million
Price / Sales
7.42
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.55 per share
Price / Book
6.34

Miscellaneous

Outstanding Shares
47,550,000
Free Float
39,323,000
Market Cap
$467.42 million
Optionable
Not Optionable
Beta
2.35

Key Executives

  • Charles S. McKhann
    President, Chief Executive Officer & Director
  • John Molesphini
    Executive Vice President-Operations
  • Jeffrey G. BlackJeffrey G. Black
    Chief Financial Officer, Secretary & Treasurer
  • Christopher J. Gostout
    Chief Medical Officer
  • Tiffanie Gilbreth
    Vice President-Clinical & Medical Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













APEN Stock - Frequently Asked Questions

Should I buy or sell Apollo Endosurgery stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Apollo Endosurgery in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" APEN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in APEN, but not buy additional shares or sell existing shares.
View APEN analyst ratings or view top-rated stocks.

What is Apollo Endosurgery's stock price forecast for 2023?

3 analysts have issued 12 month target prices for Apollo Endosurgery's shares. Their APEN share price forecasts range from $10.00 to $12.00. On average, they predict the company's stock price to reach $10.50 in the next year. This suggests a possible upside of 6.8% from the stock's current price.
View analysts price targets for APEN or view top-rated stocks among Wall Street analysts.

How have APEN shares performed in 2023?

Apollo Endosurgery's stock was trading at $9.97 at the start of the year. Since then, APEN shares have decreased by 1.4% and is now trading at $9.83.
View the best growth stocks for 2023 here.

Are investors shorting Apollo Endosurgery?

Apollo Endosurgery saw a decrease in short interest in the month of January. As of January 15th, there was short interest totaling 490,600 shares, a decrease of 10.9% from the December 31st total of 550,900 shares. Based on an average daily trading volume, of 1,040,000 shares, the days-to-cover ratio is presently 0.5 days.
View Apollo Endosurgery's Short Interest.

When is Apollo Endosurgery's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 28th 2023.
View our APEN earnings forecast.

How were Apollo Endosurgery's earnings last quarter?

Apollo Endosurgery, Inc. (NASDAQ:APEN) posted its quarterly earnings results on Tuesday, November, 1st. The biotechnology company reported ($0.28) EPS for the quarter, missing analysts' consensus estimates of ($0.21) by $0.07. The biotechnology company had revenue of $19.57 million for the quarter, compared to the consensus estimate of $17.97 million. Apollo Endosurgery had a negative trailing twelve-month return on equity of 78.73% and a negative net margin of 56.74%.

What guidance has Apollo Endosurgery issued on next quarter's earnings?

Apollo Endosurgery issued an update on its FY 2022 earnings guidance on Tuesday, November, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $75.00 million-$76.00 million, compared to the consensus revenue estimate of $73.95 million.

What other stocks do shareholders of Apollo Endosurgery own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Apollo Endosurgery investors own include Obalon Therapeutics (OBLN), Novavax (NVAX), Inovio Pharmaceuticals (INO), Onconova Therapeutics (ONTX), OPKO Health (OPK), Pfizer (PFE), Sunesis Pharmaceuticals (SNSS), Biocept (BIOC), Co-Diagnostics (CODX) and Second Sight Medical Products (EYES).

What is Apollo Endosurgery's stock symbol?

Apollo Endosurgery trades on the NASDAQ under the ticker symbol "APEN."

Who are Apollo Endosurgery's major shareholders?

Apollo Endosurgery's stock is owned by many different retail and institutional investors. Top institutional shareholders include Morris Financial Concepts Inc. (0.02%). Insiders that own company stock include Chas Mckhann, Cpmg Inc, David Pacitti, Jeffrey G Black, John R Barr, Neil Gagnon and R Kent Mcgaughy Jr.
View institutional ownership trends.

How do I buy shares of Apollo Endosurgery?

Shares of APEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Apollo Endosurgery's stock price today?

One share of APEN stock can currently be purchased for approximately $9.83.

How much money does Apollo Endosurgery make?

Apollo Endosurgery (NASDAQ:APEN) has a market capitalization of $467.42 million and generates $62.99 million in revenue each year. The biotechnology company earns $-24,680,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis.

How many employees does Apollo Endosurgery have?

The company employs 202 workers across the globe.

How can I contact Apollo Endosurgery?

Apollo Endosurgery's mailing address is 1120 SOUTH CAPITAL OF TX HWY BUILDING 1 SUITE 300, AUSTIN TX, 78746. The official website for the company is www.apolloendo.com. The biotechnology company can be reached via phone at (512) 279-5100, via email at investor-relations@apolloendo.com, or via fax at 858-678-0900.

This page (NASDAQ:APEN) was last updated on 1/30/2023 by MarketBeat.com Staff